Efficacy and safety of antidepressant monotherapy in the treatment of bipolar-II depression

International Clinical Psychopharmacology

Volumn 22, Issue 5, 2007, Pages 309-311

  Agosti, Vito ^a   Stewart, Jonathan W ^a  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

Adverse events; Bipolar II; Treatment emergent hypomania

Indexed keywords

ANTIDEPRESSANT AGENT; IMIPRAMINE; MOOD STABILIZER; PHENELZINE; PLACEBO;

ARTICLE; BIPOLAR DEPRESSION; BIPOLAR II DEPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; HUMAN; MAJOR DEPRESSION; MANIA; MONOTHERAPY; OUTPATIENT CARE; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT;

ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; DATA INTERPRETATION, STATISTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HUMANS; IMIPRAMINE; PERSONALITY INVENTORY; PHENELZINE; PRACTICE GUIDELINES; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME; UNITED STATES;

EID: 34547811668     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/YIC.0b013e3280c28410     Document Type: Article

References (11)

1. Amsterdam JD, Garcia-Espana F, Fawcett J, Quitkin FM, Reimherr FW, Rosenbaum JF, et al. (1998). Efficacy and safety of fluoxetine in treating bipolar II major depressive episode. J Clin Psychopharmacol 18:435-440.
2. Amsterdam JD, Shults J (2005). Fluoxetine monotherapy of bipolar type II and bipolar NOS major depression: a double-blind, placebo-substitution, continuation study. Int Clin Psychopharmacol 20:257-264.
3. Coryell W (1999). Bipolar II disorder: The importance of hypomania. In: Goldberg JF, Harrow M, editors. Bipolar disorders: clinical course and outcome. Washington, District Columbia: American Psychiatric Association, pp. 219-236.
4. Derogatis LR, Lipman RS, Covi L (1973). SCL-90: an outpatient psychiatric rating scale preliminary report. Psychopharmacol Bull 9:13-28.
5. Guy W (1976). EDCEU Assessment Manual for Psychopharmacology: publication ADM 76-338. Washington, District Columbia, US: Department of Health, Education, and Welfare, 218-222.
6. Hamilton M (1960). A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62.
7. Himmelhoch JM, Thase ME, Mallinger AG, Houck P (1991). Tranylcypromine versus imipramine in anergic bipolar depression. Am J Psychiatry 148:910-916.
8. Joffe RT, MacQueen GM, Marriott M, Robb J, Begin H, Young LT (2002). Induction of mania and cycle acceleration in bipolar disorder: effect of different classes of antidepressant. Acta Psychiatr Scand 105:427-430.
9. Serretti A, Artioli P, Zanardi R, Rossini D (2003). Clinical features of antidepressant associated manic and hypomanic switches in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 27:751-757.
10. Spitzer R, Endicott J (1975). Schedule for affective disorders and schizophrenia. New York State Psychiatric Institute, Dept of Biometrics.
11. Williams JB, Terman M, Link MJ, Amira L, Rosenthal NE (1999). Hypomania interview guide (including hyperthymia): retrospective assessment version (HIGH-R). Depress Anxiety 9:92-100.